基于2016年EULAR/ACR/PRINTO分类标准评估发热性狼疮患者的院内死亡率
该回顾性研究纳入157例发热性SLE患者,按2016年EULAR/ACR/PRINTO分类标准评估MAS,54例(34.3%)符合MAS。MAS组总体生存率显著低于非MAS组(64.8% vs 97.0%,p<0.001),多因素分析显示MAS与院内死亡显著相关(OR=64.5;95%CI:7.6-544.4;p<0.001)。
要点
- 发热性SLE患者中34.3%符合2016年MAS分类标准。
- MAS组总体生存率64.8%,显著低于非MAS组的97.0%。
- MAS与发热性SLE患者院内死亡独立相关(OR=64.5)。
核心结论
- 2016年MAS分类标准有助于识别发热性SLE患者中院内死亡高风险者。
研究设计与样本
- 回顾性分析2005年12月至2016年5月期间入住Severance医院的发热性SLE患者,共157例。
主要发现
- 157例中54例(34.3%)符合MAS,其中入院时42例、住院期间12例。
- 入院时即符合MAS者基线CRP、血小板、总蛋白、白蛋白、补体C3、纤维蛋白原较低,AST、ALT、总胆红素、铁蛋白、甘油三酯较高。
- MAS组总体生存率64.8%,非MAS组97.0%,差异有统计学意义(p<0.001)。
- 多因素分析显示MAS与院内死亡显著相关(OR=64.5;95%CI:7.6-544.4;p<0.001)。
关键数值与推荐
- 采用2016年EULAR/ACR/PRINTO分类标准评估MAS。
- MAS组总体生存率64.8% vs 非MAS组97.0%(p<0.001)。
- MAS与院内死亡的OR=64.5(95%CI:7.6-544.4;p<0.001)。
临床怎么用
- 对发热性SLE患者可依据2016年MAS分类标准早期识别MAS,以辅助评估院内死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the clinical significance of the 2016 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR)/Pediatric Rheumatology International Trials Organization (PRINTO) classification criteria for macrophage activation syndrome (MAS) in patients with febrile systemic lupus erythematosus (SLE). METHODS: We performed a retrospective analysis of SLE patients with fever, who were admitted to Severance Hospital between December 2005 and May 2016. Patients were evaluated for MAS using the 2016 classification criteria for MAS. Clinical features and laboratory findings were compared and overall survival rate was analyzed. Forward and backward stepwise logistic regression analysis was used to evaluate the factors associated with in-hospital mortality. RESULTS: Among 157 patients with SLE, 54 (34.3%) were considered to have MAS on admission (n = 42) and during admission (n = 12). For patients who already have MAS on admission, their baseline laboratory findings demonstrated lower CRP, platelets, total protein, albumin, complement C3, fibrinogen and higher AST, ALT, total bilirubin, ferritin, and triglyceride. The overall survival rate was significantly lower in patients with MAS than without MAS (64.8% vs. 97.0%, p < 0.001). Multivariate analysis showed that the presence of MAS was significantly associated with in-hospital mortality in febrile SLE patients (OR = 64.5; 95% CI: 7.6-544.4; p < 0.001). CONCLUSIONS: The 2016 classification criteria for MAS is useful to identify febrile SLE patients at high risk for in-hospital mortality. Monitoring febrile SLE patients with the new 2016 classification criteria might aid in the early detection of MAS.
引用
- Ahn SS, Yoo BW, Jung SM, et al. In-hospital mortality in febrile lupus patients based on 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome. Semin Arthritis Rheum. 2017. PMID: 28268026. doi:10.1016/j.semarthrit.2017.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。